Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to suggest that investors may be torn as to whether this is a good investment or not.In the past 12 months, the stock is down around 2% and has generally been stable, but its poor returns at a time when the market has been hot implies that there is some hesitation from investors.Is Pfizer indeed a value trap worth staying away from, or is this stock an underrated investment? Below, I'll make the case for both viewpoints and decide which one may be more appropriate.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool